| Pair Name | Licochalcone A, Sorafenib | ||
| Phytochemical Name | Licochalcone A (PubChem CID: 5318998 ) | ||
| Anticancer drug Name | Sorafenib (PubChem CID: 216239 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Licochalcone A, Sorafenib | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Biological Phenomena | Inhibition-->Cell metastasis | |||
| Gene Regulation | Down-regulation | Expression | MAP2K4 | hsa6416 |
| Down-regulation | Expression | MAPK8 | hsa5599 | |
| Down-regulation | Expression | PLAU | hsa5328 | |
| In Vitro Model | SK-HEP-1 | Liver and intrahepatic bile duct epithelial neoplasm | Homo sapiens (Human) | CVCL_0525 |
| Huh-7 | Adult hepatocellular carcinoma | Homo sapiens (Human) | CVCL_0336 | |
| Result | These findings first revealed the synergistic effects of LicA and Sor cotreatment against human HCC cells, further suggesting that beneficial effects on tumor regression could be confirmed through prospective clinical trials. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Synergistic antimetastatic effect of cotreatment with licochalcone A and sorafenib on human hepatocellular carcinoma cells through the inactivation of MKK4/JNK and uPA expression. Environ Toxicol. 2018 Dec;33(12):1237-1244. doi: 10.1002/tox.22630. | Click |
